Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 5/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.62 |
| ▸ | TBXA2R | P21731 | 5/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 4/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.62 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.62 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.62 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.62 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.62 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lemildipine SCHEMBL49442 | 1.00 | CYP2C9 (0.62) | CYP2C9CYP3A4TBXA2RCYP1A2CYP2C19 | |
| Lemildipine SCHEMBL29801339 | 1.00 | CYP2C9 (0.62) | CYP2C9CYP3A4TBXA2RCYP1A2CYP2C19 | |
| SCHEMBL7330272 | 0.93 | CYP2C9 (0.71) | CYP2C9CYP3A4TBXA2RCYP1A2CYP2C19 | |
| SCHEMBL9770423 | 0.93 | CYP2C9 (0.62) | CYP2C9CYP3A4TBXA2RCYP1A2CYP2C19 | |
| SCHEMBL7320951 | 0.92 | CYP2C9 (0.62) | CYP2C9CYP3A4TBXA2RCYP1A2CYP2C19 | |
| SCHEMBL9133557 | 0.91 | CYP2C9 (0.50) | CYP2C9CYP3A4TBXA2RCYP1A2CYP2C19 | |
| SCHEMBL10765397 | 0.91 | CYP2C9 (0.52) | CYP2C9CYP3A4TBXA2RCYP1A2CYP2C19 | |
| SCHEMBL7328156 | 0.89 | CYP2C9 (0.78) | CYP2C9CYP3A4TBXA2RCYP1A2CYP2C19 | |
| SCHEMBL7429254 | 0.88 | CYP2C9 (0.64) | CYP2C9CYP3A4TBXA2RCYP1A2CYP2C19 | |
| SCHEMBL7325004 | 0.88 | CYP2C9 (0.64) | CYP2C9CYP3A4TBXA2RCYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1544 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330188-A1 | PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF DIABETES | INSPHERO AG (CH) | 2023-10-19 | — | — | US | claimed |
| EP-4225296-A1 | PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF DIABETES | Insphero AG (CH) | 2023-08-16 | — | — | EP | claimed |
| WO-2022074057-A1 | PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF DIABETES | INSPHERO AG (CH) | 2022-04-14 | — | — | WO | claimed |
| EP-3981401-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT AND/OR PREVENTION OF DIABETES COMPRISING A CALCIUM CHANNEL BLOCKING AGENT AND AN INCRETIN MIMETIC | InSphero AG (CH) | 2022-04-13 | — | — | EP | claimed |
| EP-3621593-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2020-03-18 | — | — | EP | claimed |
| WO-2019194866-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2019-10-10 | — | — | WO | claimed |
| US-20190231786-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | CARDIX Therapeutics, LLC | 2019-08-01 | — | — | US | claimed |
| US-20190070184-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2019-03-07 | — | — | US | claimed |
| US-20180325907-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | CARDIX Therapeutics, LLC | 2018-11-15 | — | — | US | claimed |
| WO-2018208723-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2018-11-15 | — | — | WO | claimed |
| CN-1406129-A | Methods for treating substance abuse | ALBERT SHULMAN (AU) | 2003-03-26 | — | — | CN | claimed |
| US-20030055027-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | G. D. SEARLE & CO. (US) | 2003-03-20 | — | — | US | claimed |
| EP-1285655-A1 | STABILIZED PHARMACEUTICAL COMPOSITIONS CONTAINING CALCIUM CHANNEL BLOCKERS | Sankyo Company, Limited (JP) | 2003-02-26 | — | — | EP | claimed |
| WO-2002079778-A2 | IN VIVO DELIVERY METHODS AND COMPOSITIONS | RHEOLOGICS, INC. (US) | 2002-10-10 | — | — | WO | claimed |
| WO-2002043806-A2 | IN VIVO DELIVERY METHODS AND COMPOSITIONS | RHEOLOGICS, INC (US) | 2002-06-06 | — | — | WO | claimed |
| US-20020061835-A1 | Administering a drug to a human which is pharmaceutically effective to regulate at least one of the blood parameters used to adjust distribution of the drug through the bloodstream | RHEOLOGICS, INC. | 2002-05-23 | — | — | US | claimed |
| US-20020042405-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | SCHUH JOSEPH R (US) | 2002-04-11 | — | — | US | claimed |
| US-20020032149-A1 | Monitoring blood flow parameter of bloodstream, administering substance to organism such that an amount of substance enters bloodstream; distributing portion of amount ofsubstance target within organism | RHEOLOGICS, INC. | 2002-03-14 | — | — | US | claimed |
| WO-2002009761-A2 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND CALCIUM CHANNEL BLOCKER COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | PHARMACIA CORPORATION (US) | 2002-02-07 | — | — | WO | claimed |
| US-20010044584-A1 | In vivo delivery methods and compositions | RHEOLOGICS, INC. | 2001-11-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330188-A1 | PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF DIABETES | IAPP, SLC5A2, GLP1R | CYP2C9 2737/4885CYP3A4 2313/4885TBXA2R 379/4885 |
| US-20030055027-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | PTGER1, KCNN4, HCN1 | CYP2C9 645/4885CYP3A4 314/4885TBXA2R 343/4885 |
| US-20020042405-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | KCNN4, NR3C2, EDNRA | CYP2C9 568/4885CYP3A4 224/4885TBXA2R 178/4885 |
| US-20190070184-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | ADRB2, ADRA2C, ADRB1 | CYP2C9 1613/4885CYP3A4 967/4885TBXA2R 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.